vTv Therapeutics Inc. - (VTVT): Price and Financial Metrics


vTv Therapeutics Inc. - (VTVT): $0.93

-0.02 (-2.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VTVT Stock Summary

  • VTVT's price/sales ratio is 49.23; that's higher than the P/S ratio of 96.09% of US stocks.
  • VTVT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.2% of US stocks.
  • Revenue growth over the past 12 months for VTV THERAPEUTICS INC comes in at -80.59%, a number that bests just 1.76% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VTV THERAPEUTICS INC are ACER, LMNL, GANX, ALLT, and FKWL.
  • VTVT's SEC filings can be seen here. And to visit VTV THERAPEUTICS INC's official web site, go to www.vtvtherapeutics.com.

VTVT Valuation Summary

  • In comparison to the median Healthcare stock, VTVT's EV/EBIT ratio is 137.44% lower, now standing at -3.8.
  • Over the past 91 months, VTVT's price/sales ratio has gone down 192.

Below are key valuation metrics over time for VTVT.

Stock Date P/S P/B P/E EV/EBIT
VTVT 2023-01-30 47.2 -5.7 -4.4 -3.8
VTVT 2023-01-27 51.3 -6.2 -4.8 -4.2
VTVT 2023-01-26 50.6 -6.2 -4.8 -4.1
VTVT 2023-01-25 51.1 -6.2 -4.8 -4.2
VTVT 2023-01-24 51.0 -6.2 -4.8 -4.2
VTVT 2023-01-23 52.1 -6.3 -4.9 -4.3

VTVT Growth Metrics

    Its 5 year revenue growth rate is now at 542.71%.
  • Its 5 year net cashflow from operations growth rate is now at 53.3%.
  • The year over year price growth rate now stands at -83.46%.
Over the past 33 months, VTVT's revenue has gone down $746,000.

The table below shows VTVT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 2.018 -15.559 -21.47
2022-06-30 5.018 -10.326 -18.296
2022-03-31 5.018 -15.03 -15.753
2021-12-31 4.005 -19.308 -12.987
2021-09-30 10.395 -15.103 -4.81
2021-06-30 7.402 -16.943 -5.256

VTVT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VTVT has a Quality Grade of D, ranking ahead of 9.32% of graded US stocks.
  • VTVT's asset turnover comes in at 0.491 -- ranking 86th of 682 Pharmaceutical Products stocks.
  • TVTX, ASRT, and AMPH are the stocks whose asset turnover ratios are most correlated with VTVT.

The table below shows VTVT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.491 1 -1.393
2021-03-31 0.601 1 -5.046
2020-12-31 0.644 1 196.403
2020-09-30 0.003 1 20.944
2020-06-30 0.003 1 38.942
2020-03-31 0.212 1 -34.603

VTVT Price Target

For more insight on analysts targets of VTVT, see our VTVT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.75 Average Broker Recommendation 1.5 (Moderate Buy)

VTVT Stock Price Chart Interactive Chart >

Price chart for VTVT

VTVT Price/Volume Stats

Current price $0.93 52-week high $1.40
Prev. close $0.95 52-week low $0.38
Day low $0.93 Volume 50,500
Day high $0.98 Avg. volume 79,335
50-day MA $0.81 Dividend yield N/A
200-day MA $0.84 Market Cap 97.19M

vTv Therapeutics Inc. - (VTVT) Company Bio


vTv Therapeutics Inc., a biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company was founded in 2015 and is based in High Point, North Carolina.


VTVT Latest News Stream


Event/Time News Detail
Loading, please wait...

VTVT Latest Social Stream


Loading social stream, please wait...

View Full VTVT Social Stream

Latest VTVT News From Around the Web

Below are the latest news stories about VTV THERAPEUTICS INC that investors may wish to consider to help them evaluate VTVT as an investment opportunity.

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Elizabeth (Betzy) Keiley as Executive Vice President and General Counsel, effective immediately. “We welcome Betzy to vTv. Her years of legal expertise and deep experience in life sciences will be valuable to the vTv team,” said Paul Sekhri, Pr

Yahoo | February 1, 2023

Private equity firms in vTv Therapeutics Inc. (NASDAQ:VTVT) are its biggest bettors, and their bets paid off as stock gained 21% last week

Every investor in vTv Therapeutics Inc. ( NASDAQ:VTVT ) should be aware of the most powerful shareholder groups. With...

Yahoo | January 20, 2023

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma.

Yahoo | January 9, 2023

7 Drug Stocks That Will Soar in 2023

These drug stocks to buy look poised to generate huge profits for investors., both in 2023 and in subsequent years.

Larry Ramer on InvestorPlace | December 22, 2022

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Steven Tuch as Chief Financial Officer, effective immediately. “Steven’s success in capital raising and business development, combine

Yahoo | December 13, 2022

Read More 'VTVT' Stories Here

VTVT Price Returns

1-mo 19.25%
3-mo -7.00%
6-mo -25.00%
1-year 24.92%
3-year -55.71%
5-year -86.24%
YTD 40.31%
2022 -33.39%
2021 -46.51%
2020 9.41%
2019 -35.85%
2018 -55.91%

Continue Researching VTVT

Want to see what other sources are saying about vTv Therapeutics Inc's financials and stock price? Try the links below:

vTv Therapeutics Inc (VTVT) Stock Price | Nasdaq
vTv Therapeutics Inc (VTVT) Stock Quote, History and News - Yahoo Finance
vTv Therapeutics Inc (VTVT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7849 seconds.